For average-risk colorectal cancer screening, which test is recommended?

The recommended screening test for average-risk colorectal cancer is the immunochemical fecal occult blood test (iFOBT) every two years. This recommendation is based on the evidence suggesting that iFOBT is effective in detecting colorectal cancer at an early stage, allowing for timely intervention. The test is non-invasive, requires no bowel preparation, and can be performed at home, making it a practical choice for many patients.

The iFOBT works by detecting hidden blood in the stool, which can be an early sign of colorectal cancer or advanced adenomas. Regular screening with this method can significantly reduce mortality associated with colorectal cancer.

In contrast, other options such as yearly CT scans, annual sigmoidoscopies, or yearly colonoscopies are not recommended for average-risk individuals. Annual sigmoidoscopy and yearly colonoscopies are generally recommended for those at higher risk or for surveillance in individuals with a personal or family history of colorectal cancer. Yearly CT scans are not typically used as a standard screening method and may expose patients to unnecessary radiation without clear benefits in a screening context. Hence, iFOBT remains the preferred choice for average-risk colorectal cancer screening due to its balance of effectiveness, convenience, and safety.